Drug Ad Spending Climbs 9% in ‘06 December 28, 2006 By Jim Edwards/Brandweek NEW YORK Drug marketers are set to see another record year in advertising spending, with 2006 outlays projected to rise nearly 9 …
Comment
From Insomnia News
December 28, 2006 By Jim Edwards NEW YORK — Drug marketers are set to see another record year in advertising spending, with budgets up nearly 9% over last year.
Comment
From Insomnia News
Pam was not meeting sales quotas and was worried about losing her job. Each night she lay in bed letting various anxiety-provoking scenarios run through her mind.
Comment
From Insomnia News
Neurogen Corporation today announced that it has commenced a Phase II clinical trial in chronic insomnia patients with the Company’s insomnia agent, NG2-73. The study will measure sleep maintenance, as well as …
Comment
From Insomnia News
Current Research on Neurocrine Biosciences Inc For Neurocrine Biosciences, it’s all chemical.
Comment
From Insomnia News
Simply turning off the computer could help insomniacs get some shuteye. “Most people will have some insomnia at some point during their lives,” said Dr.
Comment
From Insomnia News
Via Thomson Dialog NewsEdge) Dec. 20–BRANFORD — Neurogen Corp. will sell $40 million worth of stock to about a dozen institutional investors this week, company officials announced Tuesday.
Comment
From Insomnia News
Somaxon Pharmaceuticals Somaxon Pharmaceuticals, Inc. today announced positive results from the company’s Phase 3 clinical trial evaluating SILENOR in elderly patients with chronic primary insomnia.
Comment
From Insomnia News
Somaxon Pharmaceuticals Inc. reported “positive results” from a Phase III clinical trial of its insomnia drug Silenor.
Comment
From Insomnia News
Legal News, Legal Jobs Network –King Pharmaceuticals, Inc. today reported the results of a binding arbitration proceeding with Elan Corporation, plc regarding an agreement concerning the development of a …
Comment
From Insomnia News
Sleep Disorder Information
